Neoadjuvant selpercatinib for advanced medullary thyroid cancer

BACKGROUND: Targeted kinase inhibitors have been increasingly utilized in the treatment of advanced medullary thyroid cancer (MTC) over the last decade. Recently, highly potent next generation selective RET inhibitors have been clinically validated, and selpercatinib was recently Food and Drug Admin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Head Neck
Autores principales: Jozaghi, Yelda, Zafereo, Mark, Williams, Michelle D., Gule‐Monroe, Maria K., Wang, Jennifer, Grubbs, Elizabeth G., Vaporciyan, Ara, Hu, Mimi I., Busaidy, Naifa, Dadu, Ramona, Waguespack, Steven G., Subbiah, Vivek, Cabanillas, Maria
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Case Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7756223/
https://ncbi.nlm.nih.gov/pubmed/33169506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.26527
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares